Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I study

Key Result

This phase I study compared pharmacokinetics and safety of biosimilar CTP55 and secukinumab but provides no detailed results in the abstract.

Key Points

• The study aims to evaluate the pharmacokinetics and safety of the biosimilar CTP55 in comparison to the reference drug secukinumab.
• Conducted as a three-arm, randomized, double-blinded trial
• Involved a single-dose administration
• Performed across multiple centers
• Targeted healthy volunteers
• Pharmacokinetic profiles were assessed for both CTP55 and secukinumab
• Safety and tolerability were compared between the two groups
• No severe adverse effects were reported during the trial